First Fentanyl Vaccine Enters Human Trials in the Netherlands, Aiming to Block Overdoses Before They Start
ARMR Sciences begins Phase 1 trials of a vaccine that trains the immune system to intercept fentanyl before it reaches the brain, a preventive approach with no precedent in addiction medicine.
Overview
A vaccine designed to prevent fentanyl overdoses has entered its first human trial, marking an unprecedented attempt to use the immune system as a frontline defense against the synthetic opioid responsible for the majority of drug overdose deaths in the United States. New York-based biotech ARMR Sciences launched the Phase 1/2 study in early 2026 at the Centre for Human Drug Research in Leiden, the Netherlands, enrolling approximately 40 healthy adults to assess safety and immune response.
The vaccine, developed at the University of Houston with funding from the U.S. Department of Defense, works by training the body to produce antibodies that bind fentanyl molecules in the bloodstream and prevent them from crossing the blood-brain barrier. If successful, it would represent the first proactive, preventive treatment for fentanyl exposure, in contrast to existing tools like naloxone that intervene only after an overdose has begun.
How the Vaccine Works
The vaccine uses a three-component design. A synthetic fragment of fentanyl is conjugated to CRM197, a deactivated diphtheria toxin protein already used in approved vaccines such as Prevnar. An adjuvant derived from E. coli toxins, known as dmLT, is added to amplify the immune response, according to ZME Science.
Once administered, the immune system recognizes the fentanyl fragment as a foreign threat and generates antibodies against it. When fentanyl subsequently enters the bloodstream, these antibodies bind to the drug molecules and form complexes too large to pass through the blood-brain barrier. This prevents fentanyl from reaching opioid receptors in the brain, blocking both the euphoric effects and the respiratory depression that causes overdose deaths, as reported by Fox News.
Critically, preclinical studies suggest the vaccine does not interfere with other opioids such as morphine, methadone, or buprenorphine, according to ZME Science. This means patients receiving medication-assisted treatment for opioid use disorder could theoretically receive the vaccine without disrupting their existing care.
Preclinical Results
Animal studies conducted by University of Houston researchers in collaboration with Tulane University produced strong results. In rat trials, the vaccine blocked 92 to 98 percent of fentanyl from reaching the brain and prevented all behavioral effects of the drug for at least 20 weeks, according to TechBuzz. Toxicology studies showed no overt toxicity even at 20 times the equivalent human dose, as reported by Fox News.
The 20-week duration of protection observed in rats could translate to approximately one year of immunity in humans, though this remains to be confirmed in clinical testing.
The Human Trial
The Phase 1 trial at the Centre for Human Drug Research, associated with the University of Leiden, will first evaluate safety and dosing in the 40 enrolled participants, who will receive a two-shot series. Researchers will monitor for adverse reactions and draw blood samples to confirm the vaccine is generating anti-fentanyl antibodies. If the safety phase succeeds, participants will be exposed to medical-grade fentanyl under clinical supervision to test whether the antibodies actually block the drug’s effects, according to TechBuzz.
Colin Haile, co-founder and scientific advisor of ARMR Sciences and a research associate professor at the University of Houston, has been developing the vaccine for years. ARMR Sciences CEO Collin Gage framed the vaccine as a paradigm shift in addiction medicine: existing interventions like naloxone and emergency medical response are reactive, deployed only after someone has already overdosed. The vaccine would instead provide standing protection, as reported by Fox News.
What We Don’t Know
Several significant questions remain unanswered. Sharon Levy, an addiction specialist at Boston Children’s Hospital who serves as a scientific adviser to the project, has acknowledged a fundamental limitation: antibody capacity is finite, meaning a sufficiently large dose of fentanyl could overwhelm the vaccine’s protection, according to ZME Science.
The vaccine also cannot prevent overdoses from other opioids or non-opioid substances, and it does not address the underlying neurobiology of addiction. Whether the immune response will be robust and durable enough in humans, as it was in rats, is the central question the trial is designed to answer.
Political vaccine hesitancy could also complicate uptake among the populations most at risk. And the competitive landscape is evolving: Marco Pravetoni at CounterX Therapeutics is developing a monoclonal antibody alternative that would provide approximately one month of protection per infusion, offering a different risk-benefit profile, according to TechBuzz.
Context
The trial arrives during a period of cautious improvement in the U.S. overdose crisis. Federal data show overdose deaths have been falling for more than two years, with approximately 72,100 deaths in the 12-month period ending September 2025, an 18.9 percent decline from the previous year, according to STAT News. Synthetic opioids, primarily illicit fentanyl, remain involved in nearly 70 percent of those deaths.
Early efforts to develop opioid vaccines date to the 1970s but produced inconsistent results. Advances in immunology and conjugate vaccine design have renewed interest. If the current trial demonstrates safety and immunogenicity, a Phase 2 efficacy trial would follow, though regulatory approval remains years away.